178 related articles for article (PubMed ID: 22868272)
1. Huntington's disease: dancing in a dish.
Zhang K; Yi F; Liu GH; Izpisua Belmonte JC
Cell Res; 2012 Dec; 22(12):1627-30. PubMed ID: 22868272
[TBL] [Abstract][Full Text] [Related]
2. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming Huntington monkey skin cells into pluripotent stem cells.
Chan AW; Cheng PH; Neumann A; Yang JJ
Cell Reprogram; 2010 Oct; 12(5):509-17. PubMed ID: 20936902
[TBL] [Abstract][Full Text] [Related]
4. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H
Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411
[TBL] [Abstract][Full Text] [Related]
5. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.
An MC; Zhang N; Scott G; Montoro D; Wittkop T; Mooney S; Melov S; Ellerby LM
Cell Stem Cell; 2012 Aug; 11(2):253-63. PubMed ID: 22748967
[TBL] [Abstract][Full Text] [Related]
6. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
[TBL] [Abstract][Full Text] [Related]
7. Modeling Huntington's disease with induced pluripotent stem cells.
Kaye JA; Finkbeiner S
Mol Cell Neurosci; 2013 Sep; 56():50-64. PubMed ID: 23459227
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
9. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.
HD iPSC Consortium
Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968
[TBL] [Abstract][Full Text] [Related]
10. Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells.
Carter RL; Chen Y; Kunkanjanawan T; Xu Y; Moran SP; Putkhao K; Yang J; Huang AH; Parnpai R; Chan AW
Stem Cell Reports; 2014 Oct; 3(4):585-93. PubMed ID: 25358787
[TBL] [Abstract][Full Text] [Related]
11. Generation of an induced pluripotent stem cell line from a Huntington's disease patient with a long HTT-PolyQ sequence.
Miller DC; Lisowski P; Genehr C; Wanker EE; Priller J; Prigione A; Diecke S
Stem Cell Res; 2023 Apr; 68():103056. PubMed ID: 36863131
[TBL] [Abstract][Full Text] [Related]
12. Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy.
Csobonyeiova M; Polak S; Danisovic L
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32213859
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
[TBL] [Abstract][Full Text] [Related]
14. Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity.
Tousley A; Kegel-Gleason KB
J Huntingtons Dis; 2016 Jun; 5(2):99-131. PubMed ID: 27372054
[TBL] [Abstract][Full Text] [Related]
15. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic alterations mediate iPSC-induced normalization of DNA repair gene expression and TNR stability in Huntington's disease cells.
Mollica PA; Zamponi M; Reid JA; Sharma DK; White AE; Ogle RC; Bruno RD; Sachs PC
J Cell Sci; 2018 Jul; 131(13):. PubMed ID: 29898922
[TBL] [Abstract][Full Text] [Related]
17. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.
Mattis VB; Tom C; Akimov S; Saeedian J; Østergaard ME; Southwell AL; Doty CN; Ornelas L; Sahabian A; Lenaeus L; Mandefro B; Sareen D; Arjomand J; Hayden MR; Ross CA; Svendsen CN
Hum Mol Genet; 2015 Jun; 24(11):3257-71. PubMed ID: 25740845
[TBL] [Abstract][Full Text] [Related]
18. Cellular Models: HD Patient-Derived Pluripotent Stem Cells.
Geater C; Hernandez S; Thompson L; Mattis VB
Methods Mol Biol; 2018; 1780():41-73. PubMed ID: 29856014
[TBL] [Abstract][Full Text] [Related]
19. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons.
Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E
Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602
[TBL] [Abstract][Full Text] [Related]
20. iPSC-based drug screening for Huntington's disease.
Zhang N; Bailus BJ; Ring KL; Ellerby LM
Brain Res; 2016 May; 1638(Pt A):42-56. PubMed ID: 26428226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
